Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Keystone, Edward C. | - |
dc.contributor.author | Genovese, Mark C. | - |
dc.contributor.author | Klareskog, Lars | - |
dc.contributor.author | Hsia, Elizabeth C. | - |
dc.contributor.author | Hall, Stephen T. | - |
dc.contributor.author | Miranda, Pedro C. | - |
dc.contributor.author | Pazdur, Jacek | - |
dc.contributor.author | Bae, Sang Cheol | - |
dc.contributor.author | Palmer, William | - |
dc.contributor.author | Zrubek, Julie | - |
dc.contributor.author | Wiekowski, Maria T. | - |
dc.contributor.author | Visvanathan, Sudha | - |
dc.contributor.author | Wu, Zhong | - |
dc.contributor.author | Rahman, Mahboob Ur | - |
dc.date.accessioned | 2022-12-20T22:00:30Z | - |
dc.date.available | 2022-12-20T22:00:30Z | - |
dc.date.created | 2022-08-26 | - |
dc.date.issued | 2009-06 | - |
dc.identifier.issn | 0003-4967 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/176731 | - |
dc.description.abstract | Objective: The phase III GO-FORWARD study examined the efficacy and safety of golimumab in patients with active rheumatoid arthritis (RA) despite methotrexate therapy. Methods: Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1, n = 133), golimumab 100 mg injections plus placebo capsules (group 2, n = 133), golimumab 50 mg injections plus methotrexate capsules (group 3, n = 89), or golimumab 100 mg injections plus methotrexate capsules (group 4, n = 89). Injections were administered subcutaneously every 4 weeks. The co-primary endpoints were the proportion of patients with 20% or greater improvement in the American College of Rheumatology criteria (ACR20) at week 14 and the change from baseline in the health assessment questionnaire-disability index (HAQ-DI) score at week 24. Results: The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p = 0.059) in the golimumab 100 mg plus placebo group, 55.1% (p = 0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p = 0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively. During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively. Conclusion: The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMJ PUBLISHING GROUP | - |
dc.title | Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Bae, Sang Cheol | - |
dc.identifier.doi | 10.1136/ard.2008.099010 | - |
dc.identifier.scopusid | 2-s2.0-67449133560 | - |
dc.identifier.wosid | 000266917100006 | - |
dc.identifier.bibliographicCitation | ANNALS OF THE RHEUMATIC DISEASES, v.68, no.6, pp.789 - 796 | - |
dc.relation.isPartOf | ANNALS OF THE RHEUMATIC DISEASES | - |
dc.citation.title | ANNALS OF THE RHEUMATIC DISEASES | - |
dc.citation.volume | 68 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 789 | - |
dc.citation.endPage | 796 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | RECEIVING CONCOMITANT METHOTREXATE | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | ADALIMUMAB | - |
dc.subject.keywordPlus | IMPROVEMENT | - |
dc.subject.keywordPlus | ETANERCEPT | - |
dc.subject.keywordPlus | INFLIXIMAB | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.identifier.url | https://ard.bmj.com/content/68/6/789 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.